サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519433

分子診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2024～2032年

Molecular Diagnostics Market Report by Product, Technology (Polymerase Chain Reactions, Hybridization, DNA Sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology, and Others), Application, End Users, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.16円
分子診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2024～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の分子診断市場規模は2023年に197億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに337億米ドルに達し、2024～2032年の間に6.1％の成長率（CAGR）を示すと予測しています。感染症や遺伝性疾患の有病率の増加、ポリメラーゼ連鎖反応（PCR）の技術進歩、高齢化人口の増加、疾患の早期発見に対する意識の高まり、政府の支援策が市場の軌道を形成する要因となっています。

分子診断市場分析：

主要市場促進要因分子診断市場は、主に慢性疾患や感染症の増加により拡大しており、その結果、正確な診断方法に対する需要が高まっています。また、ゲノム医療や個別化医療の継続的な進歩が分子診断市場の成長に寄与しています。

主要市場動向：重要な動向には、正確で迅速なPCRの需要、新しい方法論や診断技術による試薬やキットの増加が含まれます。また、非侵襲的な早期診断アプローチへの動きも需要を支えています。

地理的動向：北米は、高度な医療インフラの存在、研究開発への投資の増加、個別化医療の重視により、世界をリードしています。また、アジア太平洋は、資源利用の増加、健康に関する知識と支出の増加により、急速な発展を遂げています。

競合情勢：常に市場に貢献している主要競合企業は、Roche Diagnostics、Abbott Laboratories、QIAGEN、Bio-Rad Laboratories、Siemens Healthineers、Thermo Fisher Scientificなどです。これらの企業は、分子診断市場のシェアを維持し、新たな領域を占有するために、新技術やパートナーシップに多額の投資を行っています。

課題と機会：障壁は規制の複雑さと分子診断の財政です。課題とともに、医療プロバイダーにとっては、新興市場における医療ニーズの高まりや、より良い診断法を約束し市場を拡大する絶え間ない技術進歩から、新たなビジネス機会が生まれます。

分子診断市場傾向：

慢性疾患と感染症の蔓延

市場は著しい成長率を示しているが、これは主に急性と慢性疾患の症例が増加しているためです。がん、心臓病、感染症などの疾病の増加は、疾病の迅速かつ適切な診断を可能にする分子診断の重要な役割に注目しています。この特性は、患者の予後を改善し、また個々の患者に対応した治療計画を構成することを可能にし、市場における分子診断の需要を高めています。世界中で複雑化する健康状態に伴い、新型の分子診断装置に対する需要が高まっており、これが市場の成長を永続させています。保健省の報告によると、2016年、非感染性疾患（NCDs）は全死亡の61％、障害事例の55％を占めています。

ゲノミクスと個別化医療における技術の進歩

このセグメントでは、世界の分子診断市場動向にとって極めて重要なゲノミクスと個別化医療の進展が見られます。DNA配列決定、遺伝子発現、RNAなどの次世代DNA配列決定のための遺伝子プロファイリング革新は不可欠であり、診断方法を変え、特定の疾患マーカーや遺伝的素因の同定を可能にします。個人の遺伝子プロファイルに基づいて治療を調整する個別化医療の利用は、複雑な遺伝子情報を正確に解読できる高度な診断技術の必要性を生み出しています。高度な技術と個別化治療の連携が進み、市場シェアが拡大しています。

個別化医療報告書によると、2015年、米国のバラク・オバマ大統領は精密医療イニシアチブ（PMI）を立ち上げました。このイニシアチブは、綿密な科学研究のために、数千から始まり潜在的には100万ゲノム配列まで拡大する、広範なゲノムデータへの安全なアクセスを研究者に提供するものです。

高齢化の進展と標的診断への需要

高齢者人口における神経変性疾患や心血管疾患などの疾病の増加により、効率的な診断法に対する需要が高まっています。分子診断学は、健康状態の早期発見という貴重な機能を提供し、その結果、便利で治療成績の向上した治療への明確な道筋を記載しています。この人口統計の増加傾向は、ラボオンチップ（LOA）技術のような非侵襲的で正確なツールに対する需要を著しく高めており、これはこの新しい健康要件に適応しようとする市場セグメントの増加傾向を示しています。この人口シフトは分子診断市場分析に大きく寄与しています。

分子診断市場セグメンテーション：

IMARC Groupは、世界の分子診断市場レポートの各セグメントにおける主要動向の分析と、2024～2032年までの世界、地域、国別レベルでの予測を提供しています。製品別、技術別、用途別、エンドユーザー別に市場を分類しています。

製品別の内訳

試薬とキット

機器

ソフトウェアとサービス

試薬とキットが市場を独占

本レポートでは、製品別に市場を詳細に区分・分析しています。これには試薬とキット、機器、ソフトウェアとサービスが含まれます。報告書によると、試薬とキットが最大のセグメントを占めています。

市場は、特に試薬とキットのセグメントにおいて、分子診断学が様々な専門医療セグメントに拡大したことにより、大幅な伸びを記録しています。調査における新しいパラダイムや新しい発明は、実現可能な適切な試薬やキットを必要とする新しいアッセイや試験方法を生み出します。慢性疾患の増加は、迅速で信頼できる診断ツールの必要性をより重要なものにしており、これが増加の原動力となっています。また、大手企業と研究機関との連携も、新しい試薬やキットの開発に影響を与えるため、分子診断市場の収益拡大に大きな役割を果たしています。

技術別の内訳

ポリメラーゼ連鎖反応（PCR）

ハイブリダイゼーション

DNA配列解析

マイクロアレイ

等温核酸増幅技術（INAAT）

その他

ポリメラーゼ連鎖反応（PCR）が市場を独占

本レポートでは、技術別の市場の詳細な区分と分析を行っています。これには、ポリメラーゼ連鎖反応（PCR）、ハイブリダイゼーション、DNA配列解析、マイクロアレイ、等温核酸増幅技術（INAAT）、その他が含まれます。報告書によると、ポリメラーゼ連鎖反応（PCR）が最大のセグメントを占めています。

PCRセグメントは分子診断市場展望を支配しています。qPCRとdPCRの設計と構築を含むPCR技術の改良の出現は、増幅の生化学的プロセスを推進し、それによって感度、精度、スピードを向上させる。このようなPCRの進歩により、PCRは分子診断において不可欠な機器となりました。個別化医療や標的治療に使用できる遺伝子プロファイルの正確な分析は、今やこれらの治療に不可欠です。加えて、ポイントオブケア診断の進歩とPCRプラットフォームの採用は、医療専門家と患者の双方に分子試験をより利用しやすくし、これが医療環境間の統合を広げることにつながっています。

用途別内訳

感染症診断

腫瘍学

遺伝子試験

血液試験

その他

感染症診断が市場を独占

本レポートでは、市場を用途別に詳細に区分・分析しています。これには感染症診断、腫瘍学、遺伝子試験、血液試験、その他が含まれます。それによると、感染症診断が最大のセグメントを占めています。

分子診断市場概要では、市場力学はウイルス、細菌、真菌感染を含む感染症の急速な広がりと一致していると説明しています。特にパンデミック（世界的大流行）に陥る可能性のある疾病が急速に蔓延しているため、早期発見と実行可能な封じ込め戦略が急務となっています。診断学における分子生物学と免疫測定技術の出現は、病原体の検出と耐性菌のタイピングの精度と速度を向上させることにより、この状況に革命をもたらしました。この画期的な進歩により、分子診断学の有望な市場が創出され、予防衛生と監視プロジェクトの成長という強い動向が示されました。これらの対策は、医療に関与し、感染の拡大を食い止める上で重要な役割を果たしています。

エンドユーザー別内訳

病院

研究所

その他

本レポートでは、エンドユーザー別に市場を詳細に区分・分析しています。これには病院、研究所、その他が含まれます。

地域別の内訳

北米

米国

カナダ

アジア太平洋

中国

日本

インド

韓国

オーストラリア

インドネシア

その他

欧州

ドイツ

フランス

英国

イタリア

スペイン

ロシア

その他

ラテンアメリカ

ブラジル

メキシコ

その他

中東・アフリカ

北米が明確な優位性を示し、最大の分子診断市場シェアを占める

この調査レポートは、北米（米国、カナダ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東アフリカを含む主要地域市場の包括的な分析も行っています。同レポートによると、分子診断の地域別市場規模は北米が最大です。

北米市場は、分子診断市場の予測期間通り、永続的な研究開発イノベーションの強い文化により成長しています。がん、心血管疾患、糖尿病などの慢性疾患の増加に伴い、迅速で信頼性の高い検出方法が求められています。医療専門家や患者における個別化医療への理解度の高まりが、他の要因とともに市場成長を後押ししています。医療の近代化における政府の援助と分子診断技術の確立は、事業成長の主要な新興経済諸国ドライバーです。さらに、DTC遺伝子試験も消費者との交流レベルを向上させ、分子診断市場の最近のビジネス機会を支える重要な要素となっています。

本レポートで扱う主要質問

  • 世界の分子診断市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 分子診断世界市場促進要因、阻害要因、機会は何か？
  • 各ドライバー、阻害要因、機会が世界の分子診断市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な分子診断市場はどの国か？
  • 製品別の市場構成は？
  • 分子診断市場で最も魅力的な製品は？
  • 技術別の市場構成は？
  • 分子診断市場において最も魅力的な技術は？
  • 用途別の市場構成は？
  • 分子診断市場において最も魅力的な用途は？
  • エンドユーザー別の市場構成は？
  • 分子診断市場で最も魅力的なエンドユーザーは？
  • 分子診断世界市場の競争構造は？
  • 分子診断世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブ概要

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の分子診断市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 試薬とキット
  • 機器
  • ソフトウェアとサービス

第7章 市場内訳：技術別

  • ポリメラーゼ連鎖反応（PCR）
  • ハイブリダイゼーション
  • DNA配列解析
  • マイクロアレイ
  • 等温核酸増幅技術（INAAT）
  • その他

第8章 市場内訳：用途別

  • 感染症診断
  • 腫瘍学
  • 遺伝子試験
  • 血液試験
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院
  • 研究所
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Biomerieux SA
    • Danaher Corporation
    • Diasorin Molecular LLC（DiaSorin S.p.A.）
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Hologic Inc.
    • Illumina Inc.
    • Myriad Genetics Inc.
    • Qiagen
    • Quidel Corporation
    • Thermo Fisher Scientific
図表

List of Figures

  • Figure 1: Global: Molecular Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Molecular Diagnostics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Molecular Diagnostics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Molecular Diagnostics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Molecular Diagnostics Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Molecular Diagnostics Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Molecular Diagnostics Market: Breakup by End Users (in %), 2023
  • Figure 8: Global: Molecular Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Molecular Diagnostics (Reagents and Kits) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Molecular Diagnostics (Reagents and Kits) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Molecular Diagnostics (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Molecular Diagnostics (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Molecular Diagnostics (Software and Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Molecular Diagnostics (Software and Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Molecular Diagnostics (Polymerase Chain Reactions (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Molecular Diagnostics (Polymerase Chain Reactions (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Molecular Diagnostics (Hybridization) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Molecular Diagnostics (Hybridization) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Molecular Diagnostics (DNA Sequencing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Molecular Diagnostics (DNA Sequencing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Molecular Diagnostics (Microarray) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Molecular Diagnostics (Microarray) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Molecular Diagnostics (Isothermal Nucleic Acid Amplification Technology (INAAT)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Molecular Diagnostics (Isothermal Nucleic Acid Amplification Technology (INAAT)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Molecular Diagnostics (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Molecular Diagnostics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Molecular Diagnostics (Infectious Diseases Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Molecular Diagnostics (Infectious Diseases Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Molecular Diagnostics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Molecular Diagnostics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Molecular Diagnostics (Genetic Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Molecular Diagnostics (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Molecular Diagnostics (Blood Screening) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Molecular Diagnostics (Blood Screening) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Molecular Diagnostics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Molecular Diagnostics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Molecular Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Molecular Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Molecular Diagnostics (Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Molecular Diagnostics (Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Molecular Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Molecular Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Molecular Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Molecular Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Molecular Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Molecular Diagnostics Industry: SWOT Analysis
  • Figure 93: Global: Molecular Diagnostics Industry: Value Chain Analysis
  • Figure 94: Global: Molecular Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Molecular Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Molecular Diagnostics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Molecular Diagnostics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Molecular Diagnostics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Molecular Diagnostics Market Forecast: Breakup by End Users (in Million US$), 2024-2032
  • Table 6: Global: Molecular Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Molecular Diagnostics Market: Competitive Structure
  • Table 8: Global: Molecular Diagnostics Market: Key Players
目次
Product Code: SR112024A5726

The global molecular diagnostics market size reached US$ 19.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032. The increasing prevalence of infectious diseases and genetic disorders, technological advancements in polymerase chain reaction (PCR), growing aging population, surging awareness of early disease detection, and supportive government initiatives are factors shaping the market's trajectory.

Molecular Diagnostics Market Analysis:

Major Market Drivers: The market for molecular diagnostics is expanding primarily due to rise in chronic and infectious illnesses which in turn is leading to growing demand for accurate diagnostics methods. In addition, the continual advancements in genomic and personalized medicine are contributing to the molecular diagnostics market growth.

Key Market Trends: Substantial trends include the demand for PCR as it is accurate and fast and the increase in reagents and kits due to the new methodologies and diagnostic technologies. Besides, the movement towards non-invasive, early diagnosis approaches is also supporting the demand.

Geographical Trends: North America is the leader in the world, due to the presence of advanced medical infrastructure, more investments in R&D and a great emphasis on personalized medicine. In addition, Asia-Pacific faces a fast development through increasing resource usage and more health-related knowledge and spendings.

Competitive Landscape: The key competitive companies that are constantly contributing to the market are Roche Diagnostics, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Siemens Healthineers, and Thermo Fisher Scientific and others. These enterprises invest heavily in the new technologies and partnerships to maintain the molecular diagnostics market share and occupy new territories.

Challenges and Opportunities: The barriers are regulatory intricacies and finances of the molecular diagnostics. Along with the challenges, new opportunities emerge for healthcare providers from the growing healthcare needs in the emerging markets and from the constant technological advances which promise better diagnostics and expand the market.

Molecular Diagnostics Market Trends:

Increasing prevalence of chronic and infectious diseases

The market is exhibiting an outstanding growth rate which is mainly due to the increasing cases of acute and chronic illnesses. This increase in disease occurrence, including cancer, heart diseases, and infection focuses on the significant role of the molecular diagnostics in giving fast and proper diagnosis of the disease. This attribute enables the better patient outcomes and also constitutes individual response personalized treatment plans, which increases the molecular diagnostics demand in the market. Along with the expanding complexities of health conditions all over the world, the demand for newfangled molecular diagnostic equipment is rising, which in turn perpetuates the market growth. According to a report by the ministry of health, in 2016, non-communicable diseases (NCDs) accounted for 61% of all mortalities and 55% of disability cases.

Technological advancements in genomics and personalized medicine

The sector is experiencing developments in genomics and personalized medicine that are crucial for the global molecular diagnostics market trends. Genetic profiling innovations for DNA sequencing, gene expression, and next-generation DNA sequencing such as RNA are essential and changing the ways of diagnosis and allowing the identification of specific disease markers and genetic predispositions. The utilization of personalized medicine, which entails to tailoring treatment based on the individual's genetic profile, is creating a need for sophisticated diagnostic technologies, that is able to decipher complex genetic information accurately. The rising cooperation between sophisticated technologies and tailored treatments is expanding the market share.

According to the personalized medicine report, in 2015, U.S. President Barack Obama launched the precision medicine initiative (PMI). This initiative offers researchers secure access to an extensive array of genomic data, starting with thousands and potentially expanding to one million genome sequences, for in-depth scientific research.

Rising aging population and demand for targeted diagnostics

The demand for efficient diagnostic method is rising due to rising illnesses, such as neurodegenerative disorders and cardiovascular problems in geriatric populations. Molecular diagnostics offer a valuable functionality of early detection of health conditions, thus providing a clear path for treatment at convenient and improved outcomes. The growing trend of this demographic is significantly increasing demand for non-invasive and accurate tools such as lab-on-a-chip (LOA) technology which is indicative of an increasing market segment's inclination to adapt to this new health requirement. This population shift is a significant contributing to the molecular diagnostics market analysis.

Molecular Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global molecular diagnostics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, technology, application, and end users.

Breakup by Product:

Reagents and Kits

Instruments

Software and Services

Reagents and kits dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes reagents and kits, instruments, and software and services. According to the report, reagents and kits represented the largest segment.

The market is experiencing a significant increase, particularly in the reagents and kits segment, due to the expansion of molecular diagnostics reach into various medical areas of specialization. Fresh paradigms in research and novel inventions generate novel assays and testing methods that require the appropriate reagents and kits to be feasible. The growing number of chronic diseases make the need for fast and dependable diagnostic tools more crucial, driving the increase. Involvement of the major companies with research institutions also has an impact on the development of new reagents and kits, and hence plays a significant part in increasing the molecular diagnostics market revenue.

Breakup by Technology:

Polymerase Chain Reactions (PCR)

Hybridization

DNA Sequencing

Microarray

Isothermal Nucleic Acid Amplification Technology (INAAT)

Others

Polymerase chain reactions (PCR) dominate the market

The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reactions (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others. According to the report, polymerase chain reactions (PCR) represented the largest segment.

The PCR segment is dominating the molecular diagnostics market outlook. The advent of PCR technology refinements, including the designing and constructing of qPCR and dPCR, propel the amplification's biochemical process, thereby improves the sensitivity, accuracy, and speed. Such advancement of PCR has made it an indispensable instrument in molecular diagnostics. Precise analysis of genetic profiles which can be used in personalized medicine and targeted therapies is now essential to these treatments. Besides, the point-of-care diagnostics advancement and PCR platform introduction into both of the healthcare professionals and patients make molecular testing more available this leads broaden its integration among healthcare environments.

Breakup by Application:

Infectious Diseases Diagnostics

Oncology

Genetic Testing

Blood Screening

Others

Infectious diseases diagnostics dominate the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes infectious diseases diagnostics, oncology, genetic testing, blood screening, and others. According to the report, infectious diseases diagnostics represented the largest segment.

The molecular diagnostics market overview explains that the market dynamics are in line with rapid spread of infectious diseases, encompassing viral, bacterial, and fungal infections. The rapid spread of diseases, especially those which have the potential to plunge the world into pandemics, has caused an urgent need for early detection mechanism and the use of viable containment strategies. The advent of molecular biology and immunoassay technologies in diagnostics revolutionized this landscape by enhancing the accuracy and speed of pathogen detection and typing for their resistances. This breakthrough has led to the creation of a promising market for molecular diagnostics and indicates a strong trend of the growth of preventive health and surveillance projects. These measures play an important role in the medical involvement and stopping the spread of infections.

Breakup by End Users:

Hospitals

Laboratories

Others

The report has provided a detailed breakup and analysis of the market based on end users. This includes hospitals, laboratories, and others.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest molecular diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for molecular diagnostics.

North America market is growing due to the strong culture of perpetual research and development innovation, as per the molecular diagnostics market forecast period. With the increase in the development of chronic diseases, such as cancer, cardiovascular diseases and diabetes, the rapid and reliable detection methods are required. The increased level of personalized medicine understanding in healthcare professionals and patients alongside other factors is propelling the market growth. Development of government aid in the healthcare modernization and the establishment of molecular diagnostics techniques are the major economies drivers in the business growth. Furthermore, DTC genetic testing is also a significant part which improves the level of consumer interaction and supports the molecular diagnostics market recent opportunities.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies Inc.

Becton Dickinson and Company

Biomerieux SA

Danaher Corporation

Diasorin Molecular LLC (DiaSorin)

F. Hoffmann-La Roche AG (Roche Holding AG)

Hologic Inc.

Illumina Inc.

Myriad Genetics Inc.

Qiagen

Quidel Corporation

Thermo Fisher Scientific

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key molecular diagnostics companies are getting involved in the latest trends in the industry, such as Abbott Laboratories and Agilent Technologies Inc. Leading bio-pharmaceutical firms drive the improvements in diagnostic technology through introduction of newer, more precise, and better tested products. Besides, global giants are continuing to grow their presence across various regions with acquisitions, mergers, and different partnerships in order to increase their market share and facilitating the access to new markets. These strategic moves expand their product lines and improve the quality of their activity, catering to the all-time demand for a customized and point-of-care diagnoses. Molecular diagnostics recent developments include a merger of AI and machine learning technologies that better facilitate data analysis and enhance the accuracy of diagnostics.

Molecular Diagnostics Market News:

In May 2023, Becton Dickinson and Company announced to invest US$ 80 million in the construction of its third plant in Ciudad Juarez.

In January 2023, Agilent Technologies and Akoya Biosciences collaborated to develop multiplex-immunohistochemistry diagnostic products for tissue analysis. The companies also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.

In April 2023, Abbott announced the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

Key Questions Answered in This Report:

  • How has the global molecular diagnostics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global molecular diagnostics market?
  • What is the impact of each driver, restraint, and opportunity on the global molecular diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive molecular diagnostics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the molecular diagnostics market?
  • What is the breakup of the market based on the technology?
  • Which is the most attractive technology in the molecular diagnostics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the molecular diagnostics market?
  • What is the breakup of the market based on end users?
  • Which are the most attractive end users in the molecular diagnostics market?
  • What is the competitive structure of the global molecular diagnostics market?
  • Who are the key players/companies in the global molecular diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Molecular Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Reagents and Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Polymerase Chain Reactions (PCR)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hybridization
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 DNA Sequencing
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Microarray
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Infectious Diseases Diagnostics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Oncology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Genetic Testing
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Blood Screening
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End Users

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biomerieux SA
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Danaher Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Diasorin Molecular LLC (DiaSorin S.p.A.)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 SWOT Analysis
    • 15.3.8 Hologic Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Illumina Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Myriad Genetics Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quidel Corporation
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Thermo Fisher Scientific
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis